Dr. Sterling is a Director in the Biotechnology/Chemical Group. Her practice is focused in the biotechnology and pharmaceutical industries, where she is involved in all areas of patent procurement, exploitation and enforcement. She has significant experience in representing clients in patent reexaminations, and in patent interferences and inter partes review proceedings before the Patent Trials and Appeals Board (PTAB). Dr. Sterling’s practice also includes counseling clients on intellectual property strategy, including evaluating patent portfolios, e.g., for invalidity, non-infringement, freedom-to-operate and due diligence analyses, and she has assisted clients in devising design-around strategies for issued patents. She has also been involved in multiple pharmaceutical and biotechnology patent litigations, including those brought under the Hatch-Waxman Act.
